Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
The short answer: four gatekeepers, in this order
To start an opioid treatment program (OTP) in the United States, an operator must clear four sequenced approvals: the SAMHSA-designated State Opioid Treatment Authority (SOTA), SAMHSA’s Center for Substance Abuse Treatment (CSAT) for OTP certification under 42 CFR Part 8, the DEA for a narcotic treatment Schedule II registration under 21 CFR 1301, and a SAMHSA-approved accrediting body, either CARF or The Joint Commission. State licensure, Medicaid enrollment, Medicare OTP enrollment, and commercial payer credentialing follow. In most states, plan for 12 to 24 months from concept to first dose.
The critical path is accreditation-then-certification, not the other way around. SAMHSA’s Division of Pharmacologic Therapies will issue a provisional certification while the program pursues full accreditation, but that provisional window is only up to one year, during which the program must become accredited. Miss that window, lose the certification. Everything else, real estate, hiring, payer contracts, is downstream of these four approvals.
One more thing operators keep asking me. This is not a category where you can build first and paper it later. The DEA registration is site-specific and cannot precede state licensure, and the SOTA typically will not sign off until you have a defensible clinical model, a diversion control plan, and a real medical director on payroll.
What changed in 2024, and why it matters to a new OTP
On February 2, 2024, HHS through SAMHSA published revisions to 42 CFR Part 8, the first substantial update to the OTP treatment rules in more than 20 years. The rules took effect on April 2, 2024, with a compliance date of October 2, 2024. For anyone launching in Florida, Texas, Ohio, or any other state right now, these are the rules you are being surveyed against.
The material changes for a new operator:
- Admission criteria loosened. Admission requirements no longer rely on one year of opioid addiction for adults and two unsuccessful attempts at withdrawal management. Your intake workflow and admission note templates need to reflect this before your first survey.
- Take-home flexibility expanded. Under the new regulations, patients can receive up to 7 take-home doses of methadone in the first 14 days of treatment, and a 28-day supply after just one month of demonstrated stability. This changes your dispensing throughput assumptions and your diversion control plan.
- Telehealth induction permitted. The revised rule allows the use of telehealth for some aspects of care, reduces admission requirements, and incorporates flexibility for take-home medication. Buprenorphine can be initiated via audio-video; methadone induction still requires an in-person exam.
- Medication units in pharmacies are now on the table. 42 CFR Part 8 allows for the establishment of an OTP medication unit in a pharmacy, should the state and pharmacy space allow for one. This is a real hub-and-spoke opportunity for multi-site operators in rural markets.
As Epstein Becker Green summarized, the final rule is the first update to the OTP regulations in over 20 years and significantly increases access to lifesaving medication while easing operational restrictions, cementing some of the telehealth and take-home dose flexibilities put in place during COVID-19. If your feasibility model was built on pre-2024 assumptions, throw it out and rebuild.
The regulator stack, with real numbers
Here is the sequence I walk operators through when we build the pro forma:
- SOTA engagement (Month 0-3). Every state has one. There are 52 SOTAs across 49 states, the District of Columbia, Puerto Rico, and the Virgin Islands who provide guidance to the more than 2,000 OTPs in U.S. States and territories. The SOTA is your first phone call, not your last. Some states cap the number of OTPs, some require a certificate of need, and some, like Georgia, have historically restricted new methadone providers through moratoria that have shifted year to year.
- State licensure (Month 3-9). This is separate from SOTA approval and typically sits with the state department of health or a behavioral health licensing office. Zoning is the killer here. In several jurisdictions I have worked in, including South Carolina and Tennessee, municipalities have used dispersal ordinances or 1,000-foot-from-school buffers to block sites well after the state approved the license.
- SAMHSA CSAT certification (Month 6-12). SAMHSA’s Division of Pharmacologic Therapies, part of CSAT, certifies that an OTP conforms with federal regulations governing treatment for substance use disorders, with 42 CFR Part 8 enabling DPT to focus oversight on improving treatment. File the SMA-162 through the SAMHSA OTP Extranet.
- DEA Schedule II narcotic treatment registration (Month 9-12). Site-specific, requires state licensure in hand, and triggers 21 CFR 1304 recordkeeping requirements from day one.
- Accreditation survey (Month 12-18). CARF and The Joint Commission are the two SAMHSA-approved options. Full accreditation must be achieved within the provisional certification year.
Scale of the opportunity: In 2001, there were approximately 900 OTPs; by the end of 2023 the number grew to 2,115, and as of May 2024, SAMHSA has certified 2,151 OTPs across virtually all U.S. States and territories. That growth has not caught up with the crisis. The CDC has repeatedly reported more than 80,000 U.S. Overdose deaths per year in the most recent reporting periods, the majority involving synthetic opioids. Access gaps are the operator’s opportunity and the regulator’s pressure point.
What the P&L actually looks like
Operators come in fixated on methadone. The reimbursement story is more nuanced. Medicare’s OTP benefit pays a weekly bundled rate per patient per week for a defined episode of care. The SUPPORT Act of 2018 established a new Medicare benefit category for OUD treatment services, effective January 1, 2020, covered under Medicare Part B, and Medicare pays for these services only when delivered by a Medicare-enrolled OTP using a bundled rate based on weekly episodes of care rather than fee-for-service.
Ballpark: CMS’s national OTP bundled payment for the methadone weekly episode (HCPCS G2067) has run in the low-$200s per patient per week for several years, with the oral buprenorphine bundle (G2068) higher and injectable buprenorphine (G2069) an order of magnitude higher. For CY 2026, the drug component was updated using the most recent data files available at the time of drafting the rule (with the exception of methadone), and the non-drug component was updated based on the Medicare Economic Index, reflecting an increase of 2.7 percent for CY 2026. Do not model off a single year. Pull the CMS OTP Payment Rates page every fall and re-run.
A few things I tell every founder before we build the pro forma:
- Methadone is a low-margin, high-volume dispensing business. Your census breakeven is real and it is a function of your locality-adjusted G-code rate, your Medicaid rate (which in some states pays less than Medicare), and your commercial mix, which is usually thin.
- Buprenorphine census dilutes revenue per patient but reduces dispensing burden and diversion risk. Model both.
- Capital requirements typically land between $1.5M and $3.5M to open a single-site OTP with a defensible clinical footprint, more if you are buying real estate. Zoning fights alone have burned $200K to $400K in carrying costs on projects I have seen in Florida and North Carolina.
- OIG scrutiny is real. HHS OIG has issued multiple reports on OTP oversight and billing since Medicare enrollment opened in 2020, and toxicology billing is a favorite target. Build the compliance program before the first claim, not after the first audit letter.
As one industry analysis put it, healthcare professionals will see a seismic shift in OTP accreditation, certification, and treatment standards, with the compliance date set for October 2, 2024. If your operating model does not internalize that, a private equity buyer performing diligence in year three will find it, and it will cost you at exit.
Frequently asked questions
How long does it take to get SAMHSA OTP certification and DEA registration?
Plan 6 to 12 months for the SAMHSA piece once the SOTA has signed off and state licensure is in hand, and another 60 to 120 days for the DEA Schedule II narcotic treatment registration. Both are gated by the state work that precedes them. I tell operators to budget 12 to 24 months from LOI on a building to first dose.
Do I need CARF or Joint Commission accreditation before SAMHSA will certify my OTP?
No. A program may apply for a provisional (initial) certification as it is working toward becoming accredited by a SAMHSA-approved accrediting body, and that provisional certification is temporary, granted for up to one year, during which time the program must become accredited. The operator move is to schedule the accreditation survey the day the doors open, not six months in.
What is the role of the SOTA and how does it differ from state licensure?
The SOTA is the state’s designated authority under 42 CFR Part 8 and coordinates directly with SAMHSA on OTP oversight. State licensure is a separate track, usually managed by the state’s health department or behavioral health licensing office. In some states the SOTA sits inside the licensing agency, in others it is a distinct office. Both must approve you. Neither substitutes for the other.
How does Medicare’s weekly bundled payment work for OTPs, and how do I enroll?
CMS pays OTPs through bundled payments for OUD treatment services for Medicare Part B patients. Enrollment is through CMS Form 855B with the OTP-specific attachments, and you must already hold SAMHSA certification and DEA registration to enroll. Expect 90 to 180 days for the Medicare Administrative Contractor to process.
What changed under the 2024 update to 42 CFR Part 8, and how does it affect new OTPs?
The biggest changes for new operators: the one-year addiction history requirement for adult admission is gone, take-home methadone flexibility is expanded, telehealth induction for buprenorphine is permitted, and medication units in pharmacies are allowable subject to state law. These rules went into effect on April 2, 2024 and the compliance date was October 2, 2024, allowing time for OTPs to prepare and for states to review their regulations that impact how this rule is implemented. Build your policies, admission templates, and diversion control plan to the 2024 rule, not the legacy one, or your first survey will hurt.
References
- SAMHSA, 42 CFR Part 8 Final Rule
- SAMHSA, Become an Opioid Treatment Program (OTP)
- SAMHSA, Federal Guidelines for Opioid Treatment Programs (PEP24-02-011)
- SAMHSA, Revised Regulations for Opioid Treatment Programs (PEP25-02-025)
- CMS, OTP Payment Rates
- CMS, OTP Billing and Payment
- Epstein Becker Green, SAMHSA Final Rule Regarding OTPs
- Addiction Treatment Forum, A New Era for Opioid Treatment Programs
- AATOD, Updates to 42 CFR Part 8 Opioid Treatment Regulations